A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
第3相
実施中（募集終了）
NCT04739761
| 対象疾患 | Breast Cancer |
|---|
| 相 | 第3相 |
|---|
| スポンサー | AstraZeneca |
|---|
| ステータス | 実施中（募集終了） |
|---|
| 参加者数 | 506 名 |
|---|
| 介入（薬剤） | Trastuzumab Deruxtecan |
|---|
| 開始日 | 2021年6月22日 |
|---|
| 完了日 | 2024年2月8日 |
|---|
| 結果公開日 | 2025年5月16日 |
|---|
概要
This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).
Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)
From first dose (Day 1) to progression of disease (up to 2 years 7 months) · Percentage of participants
| Cohort 1: Trastuzumab Deruxtecan (T-DXd) | 62.7 Percentage of participants |
|---|
Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)
At 12 months · Percentage of participants
| Cohort 2: Trastuzumab Deruxtecan (T-DXd) | 61.6 Percentage of participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。